Description
Gene Delivery of Glucagon-like Peptide-1 (GLP-1) for the Treatment of Type 2 Diabetes
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02011-10-01$521,739
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2011-10-01(start date) | $521,739 | — | Gene Delivery of Glucagon-like Peptide-1 (GLP-1) for the Treatment of Type 2 Diabetes |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2012-2013-Q4-00661 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $509,868 | FY2014 |
| 236-2011-2012-Q4-00310 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $361,539 | FY2013 |
| 236-2011-2012-Q1-00941 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $508,505 | FY2012 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2011-2012-Q1-00796 · retrieved 2026-11-14.